Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full year 2023.
The Numbers:
Cash, cash equivalents and short-term investments of $154.2 million by December 31, 2023, as compared to $273.1 million by December 31, 2022.
Quarterly and full-year R&D expenses of $14.2 million and $62.2 million, respectively, as compared to $21.9 million and $74.3 million for the same periods in 2022.
Quarterly and full-year General and Administrative (G&A) expenses of $19.4 million and $63.6 million, respectively, as compared to $15.7 million and $70.4 million in the same periods in 2022.
Quarterly and full-year net loss of $18.3 million and $40.2 million, respectively, as compared to $45.0 million and $152.4 million in the comparable 2022 periods.
The report states that the decrease of $118.9 million in the company’s cash position is primarily due to the $84.1 million net cash used in operating activities, $25.0 million for the Beckley Psytech investment, and $15.0 million of additional investments to advance its development programs.
Nonetheless, the Atai team still expects its cash, marketable securities and committed term loan facility with Hercules Capital for $175 million will be enough to fund operations into 2026.
Now Read: Atai Life Sciences’ Q3 Earnings: Near $20M Burned QoQ, Says Funding ‘Sufficient’ To Streamline 2026
January’s strategic investment in Beckley Psytech added two clinical-stage assets, BPL-003 and ELE-101, to Atai’s programs. The company now owns 35.5% of Beckley Psytech, plus a time-limited right of first refusal on a future sale of the company, asset sales or other transfer of commercial rights and an indefinite right of first negotiation …